Protalix Q2 2025: Revenue $15.4M (+16% YoY), net income $164K; CFO transition, PRX-115 trial on track

Protalix BioTherapeutics, Inc.

2025-Q2 EPS reported -$0.04 vs consensus $0.03 ▼ miss (-232.0%)

Revenue from goods $15.4M (+16% YoY); net income $164K vs $2.2M loss, EPS $0.00.
Elfabrio sales to Chiesi up $8M; EMA reviews label extension for every-4-weeks dosing.
CFO Eyal Rubin steps down Aug 24, replaced by Gilad Mamlok; transition through October.
PRX-115 Phase 2 for uncontrolled gout planned H2 2025; first patient enrollment Q4 2025.
Cash $33.4M; R&D doubled to $6M on PRX-115 prep; added to Russell 2000/3000 indexes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.